Comparison of variable distributions between the women in SAVOR-TIMI 53 trial based dataset v.s. the virtual patient dataset. by Yasunori Aoki (339027)

Comparison of variable distributions between the women in SAVOR-TIMI 53 trial based dataset v.s. the virtual patient dataset. by Yasunori Aoki (339027)

<i>Med23</i> deletion causes decreased H3K9me2 occupancy among the promoter of <i>Ccl5</i> and <i>Cxcl10</i>. by Zhichao Wang (3570413)

AvcID reduces the functionality of T5 but not T7 phage. by Brian Y. Hsueh (16955722)

Subcellular levels of p53 protein in hTCEpi-TR cell lines. by Vindhya Koppaka (845151)

Purification of IgG anti-Ts5 antibodies. by Felipe Cerni (3477902)

<i>Ext1</i> mutant lungs exhibit a decrease in SHH-FGF10 signaling. by Hua He (120374)

“…<p>(A) qPCR analysis of key components of FGF signaling pathway in lungs from E14.5. …”

Trex2 expression causes a significant decrease in Distal-EJ, Alt-NHEJ, and SSA, but not HDR. by Nicole Bennardo (93380)

ApoE, MMP-9, Claudin-5, and Occludin Protein Expression. by Lu Xu (386491)

The long-term impact of sustained exposure-reducing interventions (represented by a decrease in density of female anophelines). by Azra C. Ghani (160248)

Three-, bi- and mono-functional Vγ9Vδ2 T-cell subsets decrease in HIV+ patients. by Rita Casetti (608635)

Increase of proliferating progenitor cells and decrease of terminally differentiated granule neurons in the immature dentate gyrus of <i>PC3/Tis21</i>-null mice at P14. by Stefano Farioli-Vecchioli (256006)

“…(<b>B</b>, <b>C</b>) The same significant increase is observed for the number of dividing progenitor cells, identified either as (<b>B</b>) Ki67-positive, or as (<b>C</b>) Ki67/Sox2-positive cells (1.5-fold). (<b>D</b>) The newly generated neurons (1 hour pulse of BrdU) decreased sharply (20%). …”

Cell death and reactive gliosis induced by severe IVH showed a decrease after dexamethasone treatment. by Jang Hoon Lee (5897096)

Overtrained mice show reduced signaling capacity of DLS mGluR1/5 in response to a change in the prevailing A–O contingency. by Vincent Paget-Blanc (21807763)

Nilotinib decreases HEI-193 cell viability in a time-, dose-, and growth condition- dependent manner. by Nesrin Sabha (127278)

“…(B) HEI-193 grown in PDGF media were treated with 0, 3, 5, 10 or 20 µM nilotinib up to 5 days. Trypan blue viability assay shows decreased number of viable cells at 5 days in 3 µM nilotinib, compared to vehicle shown, mean and SD of six technical replicates. …”

The 10-fold diluted reuterin-containing supernatant decreased <i>S.</i> Typhimurium χ3339 colonization in 3-D HT-29 aggregates, while the supernatant without reuterin stimulated χ3... by Rosemarie De Weirdt (320666)

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”